HCW Biologics (HCWB) EBIT (2020 - 2026)

HCW Biologics (HCWB) has reported EBIT for 7 consecutive years, with -$3.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBIT rose 8.6% year-over-year to -$3.2 million; the trailing twelve-month figure through Jun 2026 stood at -$14.4 million (down 17.31% YoY), and the FY2025 full-year result was -$13.2 million, up 55.32% from the prior year.
• EBIT advanced to -$3.2 million in Q2 2026 per HCWB's latest filing, from -$4.5 million in the prior quarter.
• Across five years, EBIT topped out at -$1.9 million in Q1 2022 and bottomed at -$15.1 million in Q2 2024.
• Historically, EBIT has averaged -$5.1 million across 5 years, with a median of -$4.0 million in 2022.
• The sharpest annual moves came in 2024 and 2025: EBIT tumbled 235.57% in 2024, then jumped 77.11% in 2025.
• Over 5 years, EBIT stood at -$5.7 million in 2022, then sank by 90.01% to -$10.8 million in 2023, then soared by 70.77% to -$3.1 million in 2024, then sank by 41.76% to -$4.5 million in 2025, then climbed by 29.04% to -$3.2 million in 2026.
• According to Business Quant data, EBIT over the past three periods registered -$3.2 million, -$4.5 million, and -$3.3 million for Q2 2026, Q4 2025, and Q3 2025 respectively.